Drug

HomeStock AnalysisDrug

Insights into pharmaceutical companies developing and marketing innovative medications.

Johnson & Johnson Forges Ahead with Robust Q2 2025 Performance Amidst Strategic Growth Initiatives

Financial Analysis Gwilym McGrew -
NEW BRUNSWICK, NJ – July 18, 2025 – In a testament to its enduring strength and adaptive strategy, Johnson & Johnson (NYSE: JNJ) today announced...

Bristol-Myers Squibb $BMY is a Screaming Buy

Financial Analysis Gwilym McGrew -
Bristol-Myers Squibb, a pharmaceutical giant, is trading far below its intrinsic value of $146.45, as calculated using the Buffett and McGrew Valuation Methods. This...

Additional Articles